Pap test DNA may spot ovarian cancer years before symptoms

NCT ID NCT07556562

Recruiting now Diagnosis Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether DNA from routine Pap smears can detect early signs of ovarian cancer in women with high-risk gene mutations. Researchers will compare genetic changes in Pap test samples with tissue removed during preventive surgery. If the method works, it could become a simple screening tool for early detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple Pap-test-based screening to catch ovarian cancer early, potentially saving lives.
What could go wrong: This is an early validation study with only 260 participants. The test may not be accurate enough for widespread use, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERMLINE MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERMLINE MUTATIONS

Contacts and locations

Locations

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
RECRUITING

Roma, Roma, 00186, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.